{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T10:47:21Z","timestamp":1792838841642,"version":"4.5.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s11938-016-0092-0","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T05:13:37Z","timestamp":1459142017000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Direct Oral Anticoagulants in Cirrhosis"],"prefix":"10.1007","volume":"14","author":[{"given":"Nicolas M.","family":"Intagliata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hillary","family":"Maitland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen H.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"issue":"2","key":"92_CR1","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2014.11.008","volume":"135","author":"MH Prins","year":"2015","unstructured":"Prins MH, Bamber L, Cano SJ, Wang MY, Erkens P, Bauersachs R, et al. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial. Thromb Res. 2015;135(2):281\u20138.","journal-title":"Thromb Res"},{"issue":"3","key":"92_CR2","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R Franchis de","year":"2015","unstructured":"de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"issue":"1","key":"92_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/liv.12211","volume":"34","author":"NM Intagliata","year":"2014","unstructured":"Intagliata NM, Henry ZH, Shah N, Lisman T, Caldwell SH, Northup PG. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding. Liver Int. 2014;34(1):26\u201332.","journal-title":"Liver Int"},{"issue":"7","key":"92_CR4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1111\/jth.13000","volume":"13","author":"J Shatzel","year":"2015","unstructured":"Shatzel J, Dulai PS, Harbin D, Cheung H, Reid TN, Kim J, et al. Safety and efficacy of pharmacological thromboprophylaxis for hospitalized patients with cirrhosis: a single-center retrospective cohort study. J Thromb Haemost. 2015;13(7):1245\u201353.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"92_CR5","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","volume":"31","author":"LP Bechmann","year":"2011","unstructured":"Bechmann LP, Sichau M, Wichert M, Gerken G, Kroger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011;31(1):75\u201382.","journal-title":"Liver Int"},{"issue":"6","key":"92_CR6","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/MCG.0b013e3181b3ab44","volume":"44","author":"L Amitrano","year":"2010","unstructured":"Amitrano L, Guardascione MA, Menchise A, Martino R, Scaglione M, Giovine S, et al. Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis. J Clin Gastroenterol. 2010;44(6):448\u201351.","journal-title":"J Clin Gastroenterol"},{"issue":"8","key":"92_CR7","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","volume":"27","author":"SB Cui","year":"2015","unstructured":"Cui SB, Shu RH, Yan SP, Wu H, Chen Y, Wang L, et al. Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B. Eur J Gastroenterol Hepatol. 2015;27(8):914\u20139.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"7","key":"92_CR8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","volume":"10","author":"MG Delgado","year":"2012","unstructured":"Delgado MG, Seijo S, Yepes I, Achecar L, Catalina MV, Garcia-Criado A, et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin Gastroenterol Hepatol. 2012;10(7):776\u201383. This is an early and large study documenting the efficacy and safety of traditional anticoagulation for the treatment of portal vein thrombosis in cirrhosis patients.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"92_CR9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","volume":"32","author":"M Senzolo","year":"2012","unstructured":"Senzolo M, M Sartori T, Rossetto V, Burra P, Cillo U, Boccagni P, et al. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis. Liver Int. 2012;32(6):919\u201327.","journal-title":"Liver Int"},{"issue":"6","key":"92_CR10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack Jr","year":"2015","unstructured":"Pollack Jr CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511\u201320.","journal-title":"N Engl J Med"},{"issue":"25","key":"92_CR11","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413\u201324. This trial shows that a reversal agent for oral factor Xa inhibitors is safe and effective. Availability of a reversal agent that does not promote hypercoagulability may make these medications even more desirable in cirrhosis patients.","journal-title":"N Engl J Med"},{"issue":"9","key":"92_CR12","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799\u2013808.","journal-title":"N Engl J Med"},{"issue":"12","key":"92_CR13","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"15","key":"92_CR14","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","volume":"369","author":"VTEI Hokusai","year":"2013","unstructured":"Hokusai VTEI, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406\u201315.","journal-title":"N Engl J Med"},{"issue":"14","key":"92_CR15","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","volume":"366","author":"E-P Investigators","year":"2012","unstructured":"Investigators E-P, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287\u201397.","journal-title":"N Engl J Med"},{"issue":"20","key":"92_CR16","first-page":"1945","volume":"368","author":"AT Cohen","year":"2013","unstructured":"Cohen AT, Spiro TE, Spyropoulos AC, Committee MS. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(20):1945\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"92_CR17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/hep.27225","volume":"61","author":"NM Intagliata","year":"2015","unstructured":"Intagliata NM, Maitland H, Northup PG, Caldwell SH. Treating thrombosis in cirrhosis patients with new oral agents: ready or not? Hepatology. 2015;61(2):738\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"92_CR18","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.26998","volume":"60","author":"M Martinez","year":"2014","unstructured":"Martinez M, Tandra A, Vuppalanchi R. Treatment of acute portal vein thrombosis by nontraditional anticoagulation. Hepatology. 2014;60(1):425\u20136.","journal-title":"Hepatology"},{"key":"92_CR19","doi-asserted-by":"crossref","unstructured":"Intagliata NM, Henry ZH, Maitland H, Shah NL, Argo CK, Northup PG, et al. Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation. Dig Dis Sci. 2016 Jan 2:1\u20137. Epub 2016\/01\/02. English. This recently published paper is the first and largest clinical study examining DOAC in cirrhosis patients with a comparison cohort of patients on traditional anticoagulants.","DOI":"10.1007\/s10620-015-4012-2"},{"key":"92_CR20","unstructured":"Pradaxa (dabigatran etexilate) [package insert]. Boehringer Ingelheim Pharmaceuticals Inc. Ridgefield, CT; 11\/2015 [cited December 6, 2015]. Available from: http:\/\/docs.boehringer-ingelheim.com\/Prescribing Information\/PIs\/Pradaxa\/Pradaxa.pdf."},{"issue":"13","key":"92_CR21","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","volume":"123","author":"GJ Hankey","year":"2011","unstructured":"Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436\u201350.","journal-title":"Circulation"},{"issue":"4","key":"92_CR22","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13181-011-0178-y","volume":"7","author":"M Ganetsky","year":"2011","unstructured":"Ganetsky M, Babu KM, Salhanick SD, Brown RS, Boyer EW. Dabigatran: review of pharmacology and management of bleeding complications of this novel oral anticoagulant. J Med Toxicol. 2011;7(4):281\u20137.","journal-title":"J Med Toxicol"},{"key":"92_CR23","unstructured":"Xarelto (rivaroxaban) [package insert]. Janssen Pharmaceuticals Inc. Titusville, NJ; 09\/2015 [cited 12\/6\/2015]. Available from: http:\/\/www.xareltohcp.com\/shared\/product\/xarelto\/prescribing-information.pdf ."},{"key":"92_CR24","unstructured":"Eliquis (apixaban) [package insert]. Bristol-Myers Squibb. New York, NY; 6\/2015. [cited 12\/6\/2015]. Available from: http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf ."},{"key":"92_CR25","unstructured":"Savaysa (edoxaban) [package insert]. Daiichi Sankyo. Tokyo, Japan. 1\/2015 [cited 12\/6\/2015]. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/206316lbl.pdf ."},{"issue":"1","key":"92_CR26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1477-9560-11-10","volume":"11","author":"W Mueck","year":"2013","unstructured":"Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J. 2013;11(1):10.","journal-title":"Thromb J"},{"issue":"2","key":"92_CR27","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11239-013-0967-z","volume":"37","author":"TA DeWald","year":"2014","unstructured":"DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis. 2014;37(2):217\u201333.","journal-title":"J Thromb Thrombolysis"},{"issue":"11","key":"92_CR28","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/jcph.540","volume":"55","author":"DA Parasrampuria","year":"2015","unstructured":"Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol. 2015;55(11):1286\u201392.","journal-title":"J Clin Pharmacol"},{"issue":"22","key":"92_CR29","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","volume":"371","author":"JE Ansell","year":"2014","unstructured":"Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141\u20132.","journal-title":"N Engl J Med"},{"issue":"5","key":"92_CR30","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa E, Camma C, Marietta M, Luongo M, Critelli R, Colopi S, et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012;143(5):1253\u201360 e1-4. This paper is a randomized trial demonstrating that prophylactic LMWH prevents portal vein thrombosis and improves long-term survival in cirrhosis patients.","journal-title":"Gastroenterology"},{"issue":"9","key":"92_CR31","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","volume":"175","author":"W Ageno","year":"2015","unstructured":"Ageno W, Riva N, Schulman S, Beyer-Westendorf J, Bang SM, Senzolo M, et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med. 2015;175(9):1474\u201380.","journal-title":"JAMA Intern Med"},{"issue":"5","key":"92_CR32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","volume":"54","author":"C Francoz","year":"2005","unstructured":"Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005;54(5):691\u20137.","journal-title":"Gut"},{"issue":"6","key":"92_CR33","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s10620-012-2548-y","volume":"58","author":"KT Werner","year":"2013","unstructured":"Werner KT, Sando S, Carey EJ, Vargas HE, Byrne TJ, Douglas DD, et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig Dis Sci. 2013;58(6):1776\u201380.","journal-title":"Dig Dis Sci"},{"issue":"12","key":"92_CR34","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1177\/0091270008324179","volume":"48","author":"J Stangier","year":"2008","unstructured":"Stangier J, Stahle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411\u20139.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"92_CR35","doi-asserted-by":"crossref","first-page":"e88390","DOI":"10.1371\/journal.pone.0088390","volume":"9","author":"W Potze","year":"2014","unstructured":"Potze W, Arshad F, Adelmeijer J, Blokzijl H, van den Berg AP, Meijers JC, et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One. 2014;9(2):e88390. This study examined in vitro anticoagulant effect in a wide range of cirrhosis patients expanding our knowledge of pharmacodynamic properties of these medications in cirrhosis.","journal-title":"PLoS One"},{"issue":"1","key":"92_CR36","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bcp.12054","volume":"76","author":"D Kubitza","year":"2013","unstructured":"Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor. Br J Clin Pharmacol. 2013;76(1):89\u201398.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"92_CR37","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","volume":"61","author":"W Potze","year":"2015","unstructured":"Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology. 2015;61(4):1435\u20136.","journal-title":"Hepatology"},{"key":"92_CR38","doi-asserted-by":"crossref","unstructured":"Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. Journal of clinical pharmacology. 2015 May 22.","DOI":"10.1002\/jcph.550"},{"issue":"3","key":"92_CR39","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.thromres.2008.02.017","volume":"123","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Eriksson BI, Cohen AT, Bergqvist D, Dahl OE, Lassen MR, et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123(3):488\u201397.","journal-title":"Thromb Res"},{"issue":"2","key":"92_CR40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jhep.2014.03.026","volume":"61","author":"S Russmann","year":"2014","unstructured":"Russmann S, Niedrig DF, Budmiger M, Schmidt C, Stieger B, Hurlimann S, et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014;61(2):293\u2013300.","journal-title":"J Hepatol"},{"issue":"6","key":"92_CR41","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/MBC.0000000000000363","volume":"26","author":"EJ Anastasia","year":"2015","unstructured":"Anastasia EJ, Rosenstein RS, Bergsman JA, Parra D. Use of apixaban after development of suspected rivaroxaban-induced hepatic steatosis; a case report. Blood Coagul Fibrinolysis. 2015;26(6):699\u2013702.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"92_CR42","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jhep.2014.05.010","volume":"61","author":"N Moore","year":"2014","unstructured":"Moore N, Blin P, Gulmez SE. New oral anticoagulants (NOAC) and liver injury. J Hepatol. 2014;61(2):198\u20139.","journal-title":"J Hepatol"},{"issue":"7","key":"92_CR43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1136\/heartjnl-2013-305288","volume":"100","author":"D Caldeira","year":"2014","unstructured":"Caldeira D, Barra M, Santos AT, de Abreu D, Pinto FJ, Ferreira JJ, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100(7):550\u20136.","journal-title":"Heart"},{"issue":"2","key":"92_CR44","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2353\/ajpath.2008.070347","volume":"172","author":"K Borensztajn","year":"2008","unstructured":"Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. Am J Pathol. 2008;172(2):309\u201320.","journal-title":"Am J Pathol"},{"issue":"11","key":"92_CR45","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2003.032136","volume":"53","author":"JG Duplantier","year":"2004","unstructured":"Duplantier JG, Dubuisson L, Senant N, Freyburger G, Laurendeau I, Herbert JM, et al. A role for thrombin in liver fibrosis. Gut. 2004;53(11):1682\u20137.","journal-title":"Gut"},{"issue":"2","key":"92_CR46","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jhep.2006.08.023","volume":"46","author":"W Abe","year":"2007","unstructured":"Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, et al. Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007;46(2):286\u201394.","journal-title":"J Hepatol"},{"issue":"2","key":"92_CR47","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1124\/jpet.114.218545","volume":"351","author":"AK Kopec","year":"2014","unstructured":"Kopec AK, Joshi N, Towery KL, Kassel KM, Sullivan BP, Flick MJ, et al. Thrombin inhibition with dabigatran protects against high-fat diet-induced fatty liver disease in mice. J Pharmacol Exp Ther. 2014;351(2):288\u201397.","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-016-0092-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-016-0092-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-016-0092-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T08:56:12Z","timestamp":1655369772000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-016-0092-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["92"],"URL":"https:\/\/doi.org\/10.1007\/s11938-016-0092-0","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}